Skip to content Skip to footer
Subscribe Now
NEWS

Splash Licenses Argent BioPharma’s CannEpil for Global Epilepsy Rights

Shots: Splash secured exclusive global rights to develop & commercialize CannEpil for drug-resistant epilepsy, refractory epilepsy, seizure disorders, & related neurological conditions, incl. future product improvements & next-generation formulations Splash secured a $1M strategic investment from C/M Capital Partners, while Mercer Street forgave ~$5M in Argent BioPharma debt and Splash issued $5.5M in preferred equity…
July 7, 2026

Read more

NEWS

Alcon Partners with RxSight to Develop Adjustable PCIOLs

Shots: Alcon has entered into a non-exclusive collaboration with RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) Under the collaboration, RxSight & Alcon will combine RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to co-develop adjustable PCIOLs for optimized cataract surgery outcomes As per the deal, RxSight will lead development & manufacturing, receiving…
July 7, 2026

Read more

Crinetics
NEWS

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Shots: Vertex has entered into a definitive agreement to acquire Crinetics, incl. its assets Palsonify (paltusotine) & atumelnant, accelerating Vertex’s revenue growth and enhancing its long-term earnings profile As per the deal, Vertex to acquire Crinetics for $85/share in cash, representing the total equity value of ~$10B, or ~$8.8B net of estimated cash acquired Palsonify (QD, PO)…
July 7, 2026

Read more

NEWS

Pharvaris Reports the US FDA’s NDA Acceptance of Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Shots: The US FDA has accepted NDA for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of Hereditary Angioedema (HAE) attacks (PDUFA: Apr 23, 2027) NDA was backed by data from >1,300 HAE attacks. In P-III (RAPIDe-3) trial, deucrictibant IR met the 1EP & all eleven 2EPs, with median times to symptom relief,…
July 6, 2026

Read more

NEWS

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Shots: Natera has reported the publication of data on Signatera, a personalized MRD test for resected colorectal liver metastases (CRLM), in JAMA Oncology, with findings also presented at the ESMO GI 2026 The analysis incl. 298 pts from the GALAXY trial, an observational arm of CIRCULATE-Japan, assessing outcomes by MRD status & adj. CT (ACT) use…
July 6, 2026

Read more

NEWS

Astex Pharmaceuticals Partners with Genentech for Breast Cancer Therapy Program in a Deal Worth Over $490M

Shots: Astex has entered into an exclusive, worldwide research collaboration & license agreement with Genentech to identify small molecules with selective inhibitory activity for the treatment for breast cancer Astex will license compounds from its breast cancer discovery program to Genentech and jointly optimize lead compounds through preclinical candidate selection, after which Genentech will lead…
July 6, 2026

Read more

NEWS

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…
July 6, 2026

Read more

Load more